{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:35Z","timestamp":1791669095540,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03408-y","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:46:21Z","timestamp":1791668781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemostatic dysfunction and thrombotic risk in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1007","author":[{"given":"Jakub","family":"Pawli\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"W\u00f3jtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Dzie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Brudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7977-9797","authenticated-orcid":false,"given":"Jakub","family":"Janczura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"3408_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966\u20131986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"3408_CR2","doi-asserted-by":"publisher","unstructured":"Li J, Zhou J, Li P et al (2025) The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis. Hepatol Commun 9. https:\/\/doi.org\/10.1097\/HC9.0000000000000689","DOI":"10.1097\/HC9.0000000000000689"},{"key":"3408_CR3","doi-asserted-by":"publisher","first-page":"e95288","DOI":"10.7759\/cureus.95288","volume":"17","author":"A Djeagou","year":"2025","unstructured":"Djeagou A, Gunukula K, Sermani A, Vaspari SK (2025) Emerging perspectives in the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review. Cureus 17:e95288. https:\/\/doi.org\/10.7759\/cureus.95288","journal-title":"Cureus"},{"key":"3408_CR4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Kalligeros M, Henry L (2024) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. https:\/\/doi.org\/10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"key":"3408_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/life14010093","volume":"14","author":"S Pezzino","year":"2024","unstructured":"Pezzino S, Luca T, Castorina M et al (2024) Role of perturbated hemostasis in MASLD and its correlation with adipokines. Life (Basel) 14:93. https:\/\/doi.org\/10.3390\/life14010093","journal-title":"Life (Basel)"},{"key":"3408_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2174\/1381612826666200131101553","volume":"26","author":"M Spinosa","year":"2020","unstructured":"Spinosa M, Stine JG (2020) Nonalcoholic fatty liver disease-evidence for a thrombophilic state? Curr Pharm Des 26:1036\u20131044. https:\/\/doi.org\/10.2174\/1381612826666200131101553","journal-title":"Curr Pharm Des"},{"key":"3408_CR7","doi-asserted-by":"publisher","first-page":"109395","DOI":"10.1016\/j.thromres.2025.109395","volume":"253","author":"DE Gonz\u00e1lez-Mendoza","year":"2025","unstructured":"Gonz\u00e1lez-Mendoza DE, Fern\u00e1ndez-Nogueira F, Uribe M et al (2025) Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE). Thromb Res 253:109395. https:\/\/doi.org\/10.1016\/j.thromres.2025.109395","journal-title":"Thromb Res"},{"key":"3408_CR8","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.jtha.2026.04.019","volume":"24","author":"S Yuan","year":"2026","unstructured":"Yuan S, Ebrahimi F, Forss A et al (2026) Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study. J Thromb Haemost 24:2910\u20132922. https:\/\/doi.org\/10.1016\/j.jtha.2026.04.019","journal-title":"J Thromb Haemost"},{"key":"3408_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.02.015","author":"N Sattar","year":"2026","unstructured":"Sattar N, Dalakoti M, Alazawi W, Aroda VR (2026) Cardiovascular risk in MASLD: What multiple lines of evidence reveal. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2026.02.015","journal-title":"J Hepatol"},{"key":"3408_CR10","doi-asserted-by":"publisher","first-page":"E699","DOI":"10.3390\/nu12030699","volume":"12","author":"A Nier","year":"2020","unstructured":"Nier A, Huber Y, Labenz C et al (2020) Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Nutrients 12:E699. https:\/\/doi.org\/10.3390\/nu12030699","journal-title":"Nutrients"},{"key":"3408_CR11","doi-asserted-by":"publisher","first-page":"770986","DOI":"10.3389\/fendo.2021.770986","volume":"12","author":"T Kessoku","year":"2021","unstructured":"Kessoku T, Kobayashi T, Imajo K et al (2021) Endotoxins and non-alcoholic fatty liver disease. Front Endocrinol (Lausanne) 12:770986. https:\/\/doi.org\/10.3389\/fendo.2021.770986","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3408_CR12","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/s41598-023-42963-9","volume":"13","author":"C-Y Kim","year":"2023","unstructured":"Kim C-Y, Kim N, Roh J-H (2023) Association of nonalcoholic fatty liver disease and venous thromboembolic disease in healthy adults in Korea: a nationwide study. Sci Rep 13:16069. https:\/\/doi.org\/10.1038\/s41598-023-42963-9","journal-title":"Sci Rep"},{"key":"3408_CR13","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.3748\/wjg.v16.i48.6119","volume":"16","author":"MND Di Minno","year":"2010","unstructured":"Di Minno MND, Tufano A, Rusolillo A et al (2010) High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 16:6119\u20136122. https:\/\/doi.org\/10.3748\/wjg.v16.i48.6119","journal-title":"World J Gastroenterol"},{"key":"3408_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41424-018-0002-y","volume":"9","author":"JG Stine","year":"2018","unstructured":"Stine JG, Niccum BA, Zimmet AN et al (2018) Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol 9:140. https:\/\/doi.org\/10.1038\/s41424-018-0002-y","journal-title":"Clin Transl Gastroenterol"},{"key":"3408_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","volume":"117","author":"W Ageno","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T et al (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93\u2013102. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.709204","journal-title":"Circulation"},{"key":"3408_CR16","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.rpth.2024.102447","volume":"8","author":"LJJ Scheres","year":"2024","unstructured":"Scheres LJJ, Br\u00e6kkan SK, Verlaan JPL et al (2024) The fatty liver index and risk of incident venous thromboembolism: the Troms\u00f8 Study. Res Pract Thromb Haemost 8:102447. https:\/\/doi.org\/10.1016\/j.rpth.2024.102447","journal-title":"Res Pract Thromb Haemost"},{"key":"3408_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.14218\/JCTH.2021.00268","volume":"10","author":"D Ogresta","year":"2022","unstructured":"Ogresta D, Mrzljak A, Cigrovski Berkovic M et al (2022) Coagulation and endothelial dysfunction associated with NAFLD: Current status and therapeutic implications. J Clin Transl Hepatol 10:339\u2013355. https:\/\/doi.org\/10.14218\/JCTH.2021.00268","journal-title":"J Clin Transl Hepatol"},{"key":"3408_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/biomedicines10020249","volume":"10","author":"A Tripodi","year":"2022","unstructured":"Tripodi A, Lombardi R, Primignani M et al (2022) Hypercoagulability in patients with non-alcoholic fatty liver disease (NAFLD): Causes and consequences. Biomedicines 10:249. https:\/\/doi.org\/10.3390\/biomedicines10020249","journal-title":"Biomedicines"},{"key":"3408_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2022.02.023","volume":"213","author":"PL Eriksen","year":"2022","unstructured":"Eriksen PL, Thomsen KL, S\u00f8rensen M et al (2022) Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. Thromb Res 213:9\u201315. https:\/\/doi.org\/10.1016\/j.thromres.2022.02.023","journal-title":"Thromb Res"},{"key":"3408_CR20","first-page":"145","volume":"16","author":"A Tripathi","year":"2026","unstructured":"Tripathi A, Singh P, Parmar V, Alam R (2026) Spectrum of Liver Diseases and Associated Coagulation Abnormalities: A Comprehensive Review. J Chem Health Risks 16:145\u2013150","journal-title":"J Chem Health Risks"},{"key":"3408_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3325\/cmj.2021.62.25","volume":"62","author":"L Virovi\u0107-Juki\u0107","year":"2021","unstructured":"Virovi\u0107-Juki\u0107 L, Stojsavljevi\u0107-Shapeski S, Forga\u010d J (2021) Non-alcoholic fatty liver disease \u2013 a procoagulant condition? Croat Med J 62:25\u201333. https:\/\/doi.org\/10.3325\/cmj.2021.62.25","journal-title":"Croat Med J"},{"key":"3408_CR22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/medicina59091614","volume":"59","author":"MA Robea","year":"2023","unstructured":"Robea MA, Balmus I-M, Girleanu I et al (2023) Coagulation dysfunctions in non-alcoholic fatty liver disease\u2014oxidative stress and inflammation relevance. Med (Kaunas) 59:1614. https:\/\/doi.org\/10.3390\/medicina59091614","journal-title":"Med (Kaunas)"},{"key":"3408_CR23","doi-asserted-by":"publisher","first-page":"26748","DOI":"10.31083\/FBL26748","volume":"30","author":"AF Sheptulina","year":"2025","unstructured":"Sheptulina AF, Liusina EO, Zlobovskaya OA et al (2025) Possible role of platelets in the development and progression of non-alcoholic fatty liver disease. Front Biosci (Landmark Ed) 30:26748. https:\/\/doi.org\/10.31083\/FBL26748","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3408_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/life14040473","volume":"14","author":"A Boccatonda","year":"2024","unstructured":"Boccatonda A, Del Cane L, Marola L et al (2024) Platelet, antiplatelet therapy and metabolic dysfunction-associated steatotic liver disease: A narrative review. Life (Basel) 14:473. https:\/\/doi.org\/10.3390\/life14040473","journal-title":"Life (Basel)"},{"key":"3408_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1530\/eje.1.01821","volume":"152","author":"C Pagano","year":"2005","unstructured":"Pagano C, Soardo G, Esposito W et al (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113\u2013118. https:\/\/doi.org\/10.1530\/eje.1.01821","journal-title":"Eur J Endocrinol"},{"key":"3408_CR26","doi-asserted-by":"crossref","unstructured":"Mertens I, Ballaux D, Funahashi T (2005) Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation Thromb Haemost","DOI":"10.1160\/TH05-01-0024"},{"key":"3408_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1210\/jc.2005-1056","volume":"91","author":"C Pagano","year":"2006","unstructured":"Pagano C, Soardo G, Pilon C et al (2006) Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91:1081\u20131086. https:\/\/doi.org\/10.1210\/jc.2005-1056","journal-title":"J Clin Endocrinol Metab"},{"key":"3408_CR28","doi-asserted-by":"publisher","first-page":"8825","DOI":"10.1038\/s41598-020-65835-y","volume":"10","author":"W Al-Hamoudi","year":"2020","unstructured":"Al-Hamoudi W, Alsadoon A, Hassanian M et al (2020) Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk. Sci Rep 10:8825. https:\/\/doi.org\/10.1038\/s41598-020-65835-y","journal-title":"Sci Rep"},{"key":"3408_CR29","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3390\/cells11162511","volume":"11","author":"N Nasiri-Ansari","year":"2022","unstructured":"Nasiri-Ansari N, Androutsakos T, Flessa C-M et al (2022) Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): A concise review. Cells 11:2511. https:\/\/doi.org\/10.3390\/cells11162511","journal-title":"Cells"},{"key":"3408_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12944-015-0141-z","volume":"14","author":"X Xu","year":"2015","unstructured":"Xu X, Lu L, Dong Q et al (2015) Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis 14:158. https:\/\/doi.org\/10.1186\/s12944-015-0141-z","journal-title":"Lipids Health Dis"},{"key":"3408_CR31","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/jcm13051406","volume":"13","author":"I Minciuna","year":"2024","unstructured":"Minciuna I, Taru MG, Procopet B, Stefanescu H (2024) The interplay between liver sinusoidal endothelial cells, platelets, and neutrophil extracellular traps in the development and progression of metabolic dysfunction-associated steatotic liver disease. J Clin Med 13:1406. https:\/\/doi.org\/10.3390\/jcm13051406","journal-title":"J Clin Med"},{"key":"3408_CR32","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan Y, Pan X, Luo J et al (2022) Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol 13:880298. https:\/\/doi.org\/10.3389\/fimmu.2022.880298","journal-title":"Front Immunol"},{"key":"3408_CR33","doi-asserted-by":"publisher","first-page":"708959","DOI":"10.3389\/fimmu.2021.708959","volume":"12","author":"TCM Fontes-Cal","year":"2021","unstructured":"Fontes-Cal TCM, Mattos RT, Medeiros NI et al (2021) Crosstalk between plasma cytokines, inflammation, and liver damage as a new strategy to monitoring NAFLD progression. Front Immunol 12:708959. https:\/\/doi.org\/10.3389\/fimmu.2021.708959","journal-title":"Front Immunol"},{"key":"3408_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jhep.2016.09.025","volume":"66","author":"A Tripodi","year":"2017","unstructured":"Tripodi A, Fracanzani AL, Chantarangkul V et al (2017) Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 66:248\u2013250. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.025","journal-title":"J Hepatol"},{"key":"3408_CR35","doi-asserted-by":"publisher","unstructured":"Alkhouri N, Kistangari G, Campbell C et al (2012) Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology 55. https:\/\/doi.org\/10.1002\/hep","DOI":"10.1002\/hep"},{"key":"3408_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2009.10.011","volume":"209","author":"S Sookoian","year":"2010","unstructured":"Sookoian S, Casta\u00f1o GO, Burgue\u00f1o AL et al (2010) Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 209:585\u2013591. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.10.011","journal-title":"Atherosclerosis"},{"key":"3408_CR37","doi-asserted-by":"publisher","unstructured":"Castelli M, Zoncap\u00e8 M, Meneguzzi A et al (2025) Platelet functional profile is altered in metabolic dysfunction-associated steatotic liver disease. Liver Int 45. https:\/\/doi.org\/10.1111\/liv.70231","DOI":"10.1111\/liv.70231"},{"key":"3408_CR38","doi-asserted-by":"publisher","first-page":"109540","DOI":"10.1016\/j.thromres.2025.109540","volume":"257","author":"F Baratta","year":"2026","unstructured":"Baratta F, Cocomello N, Carpino G et al (2026) Platelet Thromboxane B2 overproduction associated with liver fibrosis severity in patients with MASLD. Thromb Res 257:109540. https:\/\/doi.org\/10.1016\/j.thromres.2025.109540","journal-title":"Thromb Res"},{"key":"3408_CR39","doi-asserted-by":"publisher","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Friedman SL (2023) Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Transl Med 15:eadi0759. https:\/\/doi.org\/10.1126\/scitranslmed.adi0759","journal-title":"Sci Transl Med"},{"key":"3408_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5114\/ceh.2025.154220","volume":"11","author":"J Janczura","year":"2025","unstructured":"Janczura J, Mangia A, Dobrowolska K et al (2025) Steatotic liver disease and chronic viral hepatitis. Clin Exp Hepatol 11:219\u2013227. https:\/\/doi.org\/10.5114\/ceh.2025.154220","journal-title":"Clin Exp Hepatol"},{"key":"3408_CR41","doi-asserted-by":"publisher","unstructured":"Cheng Z, Chu H, Seki E et al (2024) Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis. Front Cell Dev Biol 12. https:\/\/doi.org\/10.3389\/fcell.2024.1431921","DOI":"10.3389\/fcell.2024.1431921"},{"key":"3408_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40200-025-01754-x","volume":"24","author":"K Nowak","year":"2025","unstructured":"Nowak K, Paluch M, Cudzik M et al (2025) From steatosis to cirrhosis: the role of obesity in the progression of liver disease. J Diabetes Metab Disord 24:227. https:\/\/doi.org\/10.1007\/s40200-025-01754-x","journal-title":"J Diabetes Metab Disord"},{"key":"3408_CR43","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S et al (2020) Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology 158:1611\u20131625e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"key":"3408_CR44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jhep.2021.11.004","volume":"76","author":"T Lisman","year":"2022","unstructured":"Lisman T, Caldwell SH, Intagliata NM (2022) Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 76:1291\u20131305. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.004","journal-title":"J Hepatol"},{"key":"3408_CR45","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.3390\/cancers16223844","volume":"16","author":"Y Wada","year":"2024","unstructured":"Wada Y, Okuda K, Sasaki S et al (2024) Impact of MASLD on portal vein thrombosis following hepatectomy for liver cancer. Cancers (Basel) 16:3844. https:\/\/doi.org\/10.3390\/cancers16223844","journal-title":"Cancers (Basel)"},{"key":"3408_CR46","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3390\/jcm15051787","volume":"15","author":"E Medina-Morales","year":"2026","unstructured":"Medina-Morales E, Shah Y, Xynogala A et al (2026) Impact of non-malignant portal vein thrombosis in recipients with metabolic dysfunction-associated steatotic liver disease compared to other transplant indications. J Clin Med 15:1787. https:\/\/doi.org\/10.3390\/jcm15051787","journal-title":"J Clin Med"},{"key":"3408_CR47","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.3748\/wjg.v11.i37.5834","volume":"11","author":"N Assy","year":"2005","unstructured":"Assy N, Bekirov I, Mejritsky Y et al (2005) Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 11:5834\u20135839. https:\/\/doi.org\/10.3748\/wjg.v11.i37.5834","journal-title":"World J Gastroenterol"},{"key":"3408_CR48","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.3390\/jcm11216435","volume":"11","author":"A Odriozola","year":"2022","unstructured":"Odriozola A, Puente \u00c1, Cuadrado A et al (2022) Portal vein thrombosis in the setting of cirrhosis: A comprehensive review. J Clin Med 11:6435. https:\/\/doi.org\/10.3390\/jcm11216435","journal-title":"J Clin Med"},{"key":"3408_CR49","doi-asserted-by":"publisher","first-page":"e31710","DOI":"10.1097\/MD.0000000000031710","volume":"101","author":"A-R Zeina","year":"2022","unstructured":"Zeina A-R, Kopelman Y, Mari A et al (2022) Pulmonary embolism risk in hospitalized patients with nonalcoholic fatty liver disease: A case-control study. Med (Baltim) 101:e31710. https:\/\/doi.org\/10.1097\/MD.0000000000031710","journal-title":"Med (Baltim)"},{"key":"3408_CR50","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22:1999\u20132010 e8. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3408_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12944-023-01854-8","volume":"22","author":"M Iglesias Morcillo","year":"2023","unstructured":"Iglesias Morcillo M, Freuer D, Peters A et al (2023) Association between fatty liver index and blood coagulation markers: a population-based study. Lipids Health Dis 22:83. https:\/\/doi.org\/10.1186\/s12944-023-01854-8","journal-title":"Lipids Health Dis"},{"key":"3408_CR52","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/jcm13051517","volume":"13","author":"A Boccatonda","year":"2024","unstructured":"Boccatonda A, Gentilini S, Zanata E et al (2024) Portal vein thrombosis: State-of-the-art review. J Clin Med 13:1517. https:\/\/doi.org\/10.3390\/jcm13051517","journal-title":"J Clin Med"},{"key":"3408_CR53","doi-asserted-by":"publisher","first-page":"650818","DOI":"10.3389\/fmed.2021.650818","volume":"8","author":"A Abdel-Razik","year":"2021","unstructured":"Abdel-Razik A, Mousa N, Shabana W et al (2021) De novo portal vein thrombosis in non-cirrhotic non-alcoholic fatty liver disease: A 9-year prospective cohort study. Front Med (Lausanne) 8:650818. https:\/\/doi.org\/10.3389\/fmed.2021.650818","journal-title":"Front Med (Lausanne)"},{"key":"3408_CR54","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/CIRCULATIONAHA.124.070541","volume":"150","author":"JI Weitz","year":"2024","unstructured":"Weitz JI (2024) Arterial thrombosis: Present and future. Circulation 150:905\u2013907. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.070541","journal-title":"Circulation"},{"key":"3408_CR55","doi-asserted-by":"publisher","unstructured":"Jim\u00e9nez C, Crespo J, Alonso M et al (2026) Cardiovascular risk in metabolic dysfunction associated steatotic liver disease. Cl\u00ednicas de gastroenterolog\u00eda de M\u00e9xico (English Edition) 1. https:\/\/doi.org\/10.24875\/cgme.m25000042","DOI":"10.24875\/cgme.m25000042"},{"key":"3408_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","volume":"24","author":"Y Castillo-N\u00fa\u00f1ez","year":"2024","unstructured":"Castillo-N\u00fa\u00f1ez Y, Almeda-Valdes P, Gonz\u00e1lez-G\u00e1lvez G, Arechavaleta-Granell MDR (2024) Metabolic dysfunction-associated steatotic liver disease and atherosclerosis. Curr Diab Rep 24:158\u2013166. https:\/\/doi.org\/10.1007\/s11892-024-01542-6","journal-title":"Curr Diab Rep"},{"key":"3408_CR57","doi-asserted-by":"publisher","first-page":"2306192","DOI":"10.1080\/07853890.2024.2306192","volume":"56","author":"Q Lv","year":"2024","unstructured":"Lv Q, Zhao H (2024) The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis. Ann Med 56:2306192. https:\/\/doi.org\/10.1080\/07853890.2024.2306192","journal-title":"Ann Med"},{"key":"3408_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12933-024-02263-6","volume":"23","author":"A Colantoni","year":"2024","unstructured":"Colantoni A, Bucci T, Cocomello N et al (2024) Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease. Cardiovasc Diabetol 23:175. https:\/\/doi.org\/10.1186\/s12933-024-02263-6","journal-title":"Cardiovasc Diabetol"},{"key":"3408_CR59","doi-asserted-by":"publisher","unstructured":"Jin H, Liang Z, Hu X et al (2025) Comparative association of MAFLD\/MASLD and subtypes with cardiovascular diseases outcomes. Nutr Metab Cardiovasc Dis 35. https:\/\/doi.org\/10.1016\/j.numecd","DOI":"10.1016\/j.numecd"},{"key":"3408_CR60","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jacbts.2024.12.004","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, Kumar P, Yadav SK et al (2025) Recent pathophysiological insights are advancing the treatment of venous thromboembolism. JACC Basic Transl Sci 10:689\u2013703. https:\/\/doi.org\/10.1016\/j.jacbts.2024.12.004","journal-title":"JACC Basic Transl Sci"},{"key":"3408_CR61","doi-asserted-by":"publisher","first-page":"100598","DOI":"10.1016\/j.jhepr.2022.100598","volume":"4","author":"L Valenti","year":"2022","unstructured":"Valenti L, Tripodi A, La Mura V et al (2022) Clinical and genetic determinants of the fatty liver-coagulation balance interplay in individuals with metabolic dysfunction. JHEP Rep 4:100598. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100598","journal-title":"JHEP Rep"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03408-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03408-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03408-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:46:22Z","timestamp":1791668782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03408-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":61,"alternative-id":["3408"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03408-y","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}